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Summary Despite the presence of a lymphocytic infiltrate in solid cancers, the failure for tumour growth to be contained suggests an
inadequate immune response to the tumour. Poor cytotoxicity exerted by tumour-infiltrating lymphocytes (TILs) against tumour cells in vitro,
combined with continued tumour growth in vivo, suggests deficiencies in TIL function or numbers. Various theories have been postulated to
explain how tumour cells may escape immunosurveillance and control. One of the many hypotheses is the failure of production of cytokines,
which are necessary for T cells to mediate their function. Thus, the expression of cytokine mRNA in human breast tumour sections was
investigated by reverse transcriptase polymerase chain reaction (RT-PCR) with cytokine-specific primers. A relatively consistent finding was
detection of interleukin (IL) 10 mRNA among the tumours. No IL-2 and little IL-4 mRNA was detected in the tumours. IL-6 and IL-10 mRNA
was detected in only one and two of the normal breast tissues respectively. IL-2, IL-4 and tumour necrosis factor (TNF)-a mRNA was
not detected in any of the normal breast tissues. The reduced function of TILs may be related to IL-10, which has known inhibitory effects on
T-cell activation.
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Within solid human tumours there is usually a mononuclear
infiltrate consisting predominantly of T lymphocytes, with few
B lymphocytes, natural killer (NK) cells and macrophages
(Whiteside et al, 1986; Topalian and Rosenberg, 1990). The
expression ofHLA-DR, CD25 and CD71 (transferrin receptor), on
the majority oftumour-infiltrating lymphocytes (TILs) from breast
cancers suggested that the T cells have been activated in vivo
(Whitford, et al, 1990; Chin et al, 1992; Whitford et al, 1992;
Ostenstad et al, 1994). However, the failure to contain tumour
growth suggests deficiencies in TIL function or numbers. In
support of this, freshly isolated TILs show poor cytotoxicity
against autologous and allogeneic tumour cells and poorprolifera-
tive responses to mitogen and alloantigen stimulation, although
the cytotoxicity levels of TILs can be increased by stimulation
with recombinant interleukin (rIL)-2 (Heo et al, 1987; Miescher et
al, 1987; Reilly and Antognetti, 1991; Wimmenauer et al, 1991).
Selective expression of cytokines by TILs has been reported in
melanoma, ovarian and brain tumours (Pisa et al, 1992; Merlo et
al, 1993; Luscher et al, 1994). The local production of cytokines
by TILs within the tumour microenvironment is crucial in
mounting an immune response to tumour cells, and thepresence of
suppressive cytokines might thwart the effector response. Failure
to stimulate the production ofparticular cytokines may inhibit the
functions of TILs directed against the tumour cells. This study
investigated the stable cytokine mRNA levels in freshly excised
human breast tumours, using a reverse transcriptase polymerase
chain reaction (RT-PCR) assay. The presence of cytokine mRNA
was found to be heterogeneous among individual tumours with a
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Table 1 Clinical features of patients with breast cancer
Case number Age Histology Grade LN involvement
17 64 IDC III 0/14
113 42 IDC IlIl ND
116 38 IDC II 1/11
118 63 IDC II 2/18
119 80 IDC Ill ND
120 62 IDC II 0
121 77 ILC ND ND
122 77 IDC III 0/16
123 76 IDC 11 1/4
124 38 ILC ND 0/12
125 68 ILC ND ND
126 56 IDC III 0/35
127 78 IDC 11 0/20
128 55 IDC III 2/20
130 33 IDC II 0/14
131 58 IDC 0/11
148 61 IDC 0/15
162 57 IDC 0/16
164 48 IDC 12/19
166 57 IDC 2/23
170 45 IDC III 2/25
172 69 IDC 1/20
J17 70 IDC III 2/26
J18 41 IDC 11 4/15
J24 74 IDC 111 2/15
J33 42 IDC III 32/38
J38 66 IDC II 0/18
Each breast tumour was characterized by histological examination and
analysed independently. The above clinical features were recorded for this
study, including the age of the patient, the type and grade (Bloom and
Richardson) of the diagnosed breast tumour and the number of axillary
lymph nodes with positive tumour involvement in the total number of lymph
nodes examined histologically. IDC, infiltrating ductal carcinoma; ILC,
invasive lobular carcinoma; LN, lymph node; ND, not determined.
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Table 2 Nucleotide sequences of primer pairs
Gene Primer sequence No. of base pairs
ofamplified product
,-Actin Sense TGACGGGGTCACCCACACTGTGCC 661
Antisense CTAGAAGCATTGCGGTGGACGATG
IL-2 Sense ATGTACAGGATGCAACTCCTGTGTT 458
Antisense GTCAGTGTTGAGATGATGCTTTGAC
IL-4 Sense GGGTCTCACCTCCCAACTGCT 301
Antisense CGAACACTTTGAATATTTCTCTCTC
IL-6 Sense TGAACTCCTTCTCCACAAGCGC 627
Antisense GMGACCCCTCAGGCTGGACT
IL-10 Sense CTGAGAACCAAGACCCAGACATCA 301
Antisense CAATAAGGTTTCTCAAGGGGCTGG
TNF-a Sense CGAGTGACMGCCTGTAGCCC 440
Antisense TGATCCCAAAGTAGACCTGCCC
CD36 Sense GTACTGAGCATCATCTCGATG 309
Antisense CTGGACCTGGGAAAACGCATC
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Figure 1 Detection of amplified cytokine products in a representative breast
tumour (130) and normal breast tissue (Nb5). PHA-stimulated PBLs were
used as positive controls for cytokine mRNA expression. Total RNA was
isolated from frozen tissue sections, cDNA synthesized in a reverse-
transcription reaction at 370C and RT-PCR performed using cytokine-specific
primers. Amplified products were analysed by gel electrophoresis. Amplified
product sizes include: j-actin, 661 bp; IL-2, 458 bp; IL-4, 301 bp; IL-6,
627 bp; TNF-a, 440 bp; IL-10, 301 bp
high incidence of IL-10 mRNA detected. On the other hand, IL-6
and IL-10 mRNA was detected in only one and two ofthe normal
breast tissues respectively.
MATERIALS AND METHODS
Patients
Breast tissue samples were obtained from the Department of
Histopathology at the Flinders Medical Centre, Adelaide,
Australia. Ethics approval was given by the Committee for
Clinical Investigation for the use of human tissue in this project.
Within an hour of surgical removal, the tissues were embedded in
Tissue-Tek (Miles, USA, lot no. 0885053), snap frozen in isopen-
tane cooled by liquid nitrogen. A total of 26 breast tumours were
examined for cytokine mRNA expression. Normal breast tissue
samples were collected from five patients undergoing breast
reduction and from sites remote to the tumour site in six patients
undergoing total mastectomy. Histological diagnosis of the
tumours was performed separately by a histopathologist. The clin-
ical features of the breast cancer patients are outlined in Table I
Among the 25 breast tumours examined by immunohistochem-
istry, 22 were infiltrating ductal carcinomas ofdifferent grades and
three invasive lobular carcinomas as assessed histologically.
Cryostat sectioning
Cryostat serial sections from the frozen tissue blocks were cut at a
setting of 6 ,um at -20°C, fixed on albumin-coated glass slides in
ice-cold acetone for 5 min, air dried for 2-3 hours and stored at
-20°C. Sections cut at a setting of 20 ,um were used in the extrac-
tion oftotal RNA.
Peripheral blood lymphocyte isolation
A 20-ml aliquot of peripheral blood was collected from a volun-
teer and diluted 1:1 with phosphate-buffered saline (PBS). The
diluted blood was overlayed onto 10 ml ofLymphoprep (Nycomed
Pharma AS, Prod No 1001967) and centrifuged at 2000g for
20 min. The interface layer containing mostly lymphocytes was
collected, washed twice with PBS and the cell pellet resuspended
at 1 x 106 cells ml' in RPMI-1640 medium + 10% fetal calfserum
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Table 3 Detection of cytokine mRNA in breast tumours
Tumour IL-2 IL-4 IL-6 IL-10 TNFa
17 - - + + -
113 - - + + +
116 - - + + +
119 - - - - -
120 - ND + + +
121 - - -
122 - - - + +
123 - - - + -
124 - - + + -
125 - - - - -
126 - - -
127 - - - - -
128 - - + + +
130 - - + + +
131 - + -+ +
148 - - - +
162 - - + - -
164 - - + + +
166 - + + - -
170 - - + +
172 ND - + - ND
J17 - _ + + +
J18 -
J24 - _ _ + _
J33 ND - - - -
J38 - - - + -
Within an hour of surgical removal, breast tumours were snap frozen in liquid
nitrogen-cooled isopentane. Total RNA was isolated from frozen tissue
sections, cDNA synthesized and subsequently used in PCR assays with
cytokine-specific primer pairs. All tissues showed positive amplification of
1-actin mRNA. All tissues showed amplification of CD36 mRNA, indicating
the presence of TILs. Total RNA isolated from PHA-stimulated PBLs was
used for a positive control for amplification of cytokine mRNA. The amplified
products were electrophoresed on a 2% agarose gel, stained with ethidium
bromide and viewed under UV illumination. +, amplified product detected;
-, no amplified product detected; ND, not determined.
Table 4 Detection of cytokine mRNA in normal breast tissues
Normal IL-2 IL-4 IL-6 IL-10 TNF-a
Nbl - - - - -
Nb2 - - - - -
Nb3 - -
Nb4 -
Nb5 - - + - -
Nb6 - - - - -
Nb7 - -
Nb9 - - - - ND
Nbl0 - - - + -
Nb1 - - - + -
Nbl2 - - - - -
Within an hour of surgical removal, normal breast tissues were snap frozen in
liquid nitrogen-cooled isopentane. Total RNA was isolated from frozen tissue
sections, cDNA synthesized and subsequently used in PCR assays with
cytokine-specific primer pairs. All tissues showed positive amplification of ,B-
actin mRNA. All tissues showed positive amplification of CD36 mRNA,
indicating the presence of TILs. Total RNA isolated from PHA-stimulated
PBLs was used for a positive control for amplification of cytokine mRNA. The
amplified products were electrophoressed on a 2% agarose gel, stained with
ethidium bromide and viewed under UV illumination. +, amplified product
detected; -, no amplified product detected; ND, not determined.
(FCS). The cells were stimulated with phytohaemagglutinin
(PHA) at a final concentration of 5,u ml-' for 5 or 24 h in a 37°C
incubator with a 5% carbon dioxide atmosphere.
Total RNA extraction from cellular suspensions
Cytoplasmic RNA was prepared according to (Beckman et al,
1994). Briefly, cellular suspensions were centrifuged for 12 000 g
for 2 min, washed twice in diethylpurocarbonate (DEPC)-treated
PBS, pH 7.2, by centrifuging at 6500g for 2 min at room tempera-
ture. The pellet was resuspended in 100 gl ofNP-40 lysis solution
(0.025 M sodium chloride, 0.5 M Tris-HCl, pH 7.5, 0.05 M, magne-
sium chloride, 10% (v/v) NP-40, 200 mm vanyl ribonucleoside
complexes [VRCs] (Gibco BRL no. 5522A), vortexed for 10 s and
centrifuged at 6500 g for 1 min to pellet the nuclei. The super-
natant was carefully transferred to a new Eppendorftube to which
300 gl ofbuffer A (0.08 M sodium acetate, 0.1 M sodium chloride,
0.0002 M EDTA) and 10gl of 20% sodium dodecyl sulphate
(SDS) was added and mixed well. An equal volume of phenol-
chloroform-isoamyl alcohol (PCI) was added, mixed well and
centrifuged for 5 min at 13 000 g at room temperature! The upper
aqueous phase was collected and the extraction with PCI repeated.
In the final extraction, an equal volume of chloroform - isoamyl
alcohol (24:1) alone was used to remove any traces ofphenol. The
upper aqueous layer was stored at -70°C.
Total RNA extraction from frozen tissue
A range of 3-5 serial sections of frozen breast tissue of 20-lm
thickness were cut and placed into 800 g1 of ice-cold RNAzol B
solution (Biotec Laboratories, cat no. CS-104) and total RNA
isolated according to manufacturer's instructions. Briefly, the solu-
tion was homogenized for 5 min using a hand pellet mixer. An 80-
g1 aliquot ofchloroform-isoamyl alcohol was added, incubated at
4°C for 5 min and centrifuged for 15 min at 12 000 g at 4°C. The
upper aqueous layer was precipitated with 400 ,l of isopropanol
for45 min at4°C. Aftercentrifuging at 12 000g for 15 min at4°C,
the RNA pellet was washed with 75% alchohol, briefly air dried
and redissolved in diethyl pyrocarbonate-treated water (0.1% v/v;
DEPC, Sigma Chemical, USA, cat no. D-5758).
RT-PCR assay
First-strand synthesis of cDNA from total RNA extracted from
PHA-stimulated peripheral blood lymphocytes (PBLs) or frozen
breast tissue as described above was performed at 37°C using
1.5 gl of Moloney murine leukaemia virus reverse transcriptase
(200 units ml-'; Gibco, cat. no. 8025SB) in the presence ofdNTPs
at a final concentration of 1.25 mm each (Promega, cat. no.
U1240), DTT (Gibco, cat. no. Y00147), RNasin (40 000 units ml-';
Promega, cat. no. N2511) and oligo dT (0.8 gg p1-1; Promega, cat.
no. CllOA). RT-PCR assays were performed using cDNA as
template in the presence of sense and antisense primer mixes (see
Table 2) in final volumes of50p1. The sequence ofthe primers was
designed to amplify both introns and exons of a region of the
desired gene to ensure amplification of cDNA and not genomic
DNA. Amplification of P-actin mRNA was used as a positive
control for intact mRNA ofany source. Amplification ofthe CD38
mRNA was a positive control for the presence of T lymphocytes.
In each RT-PCR assay, cDNA synthesized from total RNA
extracted from PHA-stimulated peripheral blood lymphocytes was
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used as positive controls for amplification of cytokine mRNA. In
the 36 cycles using a Perkin Elmer thermal cycler, the denaturation
step was at 94°C for 60 s, the annealing step at 55°C for 120 s and
the final extension step at74°C for 3 min. Amplified products were
electrophoresed in 2% agarose gels, stained with ethidium bromide
and photographed under UV transillumination.
RESULTS
Cytokine gene transcription
The transcription of the IL-2, IL-4, IL-6, IL-1O and TNF-a genes
was examined by RT-PCR in 26 tumours and 11 normal breast
tissues. Figure 1 illustrates the amplified products for a representa-
tive breast tumour and normal breast tissue. Tables 3 and 4
summarize the detection of cytokine mRNA expression in
human breast tumours and normal breast tissues respectively.
Amplification of 0-actin mRNA was successful in each tissue
sample. Each tissue sample showed positive amplification of
CD36 mRNA, indicating the presence of TILs in the total RNA
isolated from each tissue. IL-2 mRNA was not detected in any of
the tumours. IL-4 mRNA was detected in only 2 of 26 tumours.
By contrast, in 13 of 26 tumours, IL-6 mRNA was detected and
TNF-a mRNA was detected in 9 of26 tumours. IL-IO mRNA was
detected in 16 of26 tumours.
In contrast to the pattern of cytokine expression in the tumour
tissues, IL-10 mRNA was detected in only two of the normal
tissues and IL-6 mRNA was detected in only one of these cases.
IL-2, IL-4 and TNF-a mRNA were not detected in any of the
normal breast tissues.
DISCUSSION
In this study, the expression of cytokine mRNA expression in
human breast tumours and normal breast tissues was investigated.
Heterogeneous cytokine mRNA profiles were observed within the
tumours. A consistent feature was the inability to detect IL-2 and
IL-4 mRNA in the breast tumours. In contrast, IL-10 mRNA was
detected in over 50% ofthe tumours. Lackofdetection ofIL-2 and
IL-4 mRNA combined with the growth of breast carcinomas
suggested a failure ofTIL activation.
IL-10 mRNA was detected in more than 50% of the tumours.
IL-10 is known to have inhibitory effects on T-cell proliferation
and function as well as IL-2 production (De Waal Malefyt et al,
1991a, b; 1993) Moreover, IL-10 has also been shown to inhibit
antigen presentation by macrophages and Langerhans cells (LCs)
as well as the presentation of tumour-associated antigens by
tumour cells (Ding et al, 1993; Enk et al, 1993; Matsuda et al,
1994; Beissert et al, 1995). The detection ofIL-lO mRNA in more
than half of the breast tumours and the failure to detect IL-2
mRNA is consistent with previous work shown by others that IL-
10 may have an inhibitory role on IL-2 production and T-cell
activation. Indeed, lack ofdetection ofIL-2 expression with selec-
tive expression of IL-10 in TILs derived from human renal cell
carcinoma (RCC) was recently reported in human renal cell
carcinomas, further implicating a role for IL-10 in the immuno-
suppression ofTILs (Nakagomi et al, 1995).
Production ofIL-10 is associated with the induction ofanergy in
T lymphocytes. Becker et al (1993) demonstrated the association
of IL-10 with the induction of clonal anergy of a human CD4+ T-
cell clone by autologous MHC class II+ melanoma. Co-culturing of
the melanoma-derived CD4+ T-cell clone with the melanoma cell
line derived from the same patient failed to induce T-cell prolifera-
tion or IL-2 production. This induction of anergy was accompa-
nied by high amounts ofIL-1O mRNA and protein with very little
IL-2 produced as detected by ELISA assays and RT-PCR assays
(Becker et al, 1994). Co-culturing of the CD4+ T-cell clone with
the same autologous melanoma cells transfected with B7 cDNA
resulted in IL-2 production, T-cell proliferation as well as signifi-
cantly lower levels of IL-10 mRNA and protein (Becker et al,
1994). This suggested that IL-10 was important in maintaining
anergy in T-cell clones that had been stimulated by autologous
MHC class II+ tumour cells in the absence ofco-stimulatory mole-
cules. The failure to detect IL-2 mRNA but the detection ofIL-1O
mRNA in the breast tumours may reflect the cytokine expression
of TIL that have been rendered unresponsive or anergic. The
source of IL-10 mRNA remains under question in light of recent
studies that have demonstrated production of IL-10 by different
human carcinoma cell lines (Gastl etal, 1993; Smith et al, 1994). It
is possible that the tumour cells themselves may secrete IL-10 to
inhibit T-cell function directly or indirectly by inhibiting the
presentation ofantigen by tumour cells orAPCs. In situ hybridiza-
tion or in situ PCR would confirm the source of
IL-lO mRNA in these tumours.
The cytokine mRNA pattern was compared between individual
tumours characterized by different clinical parameters, such as
local vs metastatic tumours, and infiltrating ductal carcinomas of
different grades, to determine if any significant trends would
emerge. However, no differences or correlations were observed in
any ofthese comparisons. This suggested that the cytokine expres-
sion was characteristic of individual breast tumours and was not
directly related to clinical features or the density of lymphocytic
infiltration.
In summary, we found that the cytokine mRNA expression in
breast tumours was heterogeneous. The striking result ofthis study
was the strong presence of IL-10 mRNA in the majority of
tumours and the lack ofdetection of IL-2 and IL-4 mRNA. These
results suggest that whereas TILs may have been previously
activated, their anti-tumour activity may be suppressed by the
presence of IL-10. Thus, the presence of IL-10 in aggressively
growing tumours may reflect an inhibitory role of IL-10 on T-cell
function as well as a crucial role in maintaining anergy.
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